New probiotic bug passes first safety test in small human trial

NCT ID NCT07285317

Completed Knowledge-focused Sponsor: Spanish National Research Council Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested whether a new probiotic bacterium called Phascolarctobacterium faecium is safe and well-tolerated when taken daily as a pill for 15 days. Twenty adults—some with normal weight and some with overweight or early blood sugar issues—participated. Researchers monitored digestive symptoms, blood tests, and overall health to check for side effects. The study does not aim to treat any condition, only to see if the bacterium is safe enough for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Phascolarctobacterium faecium (a probiotic bacterium taken as a pill)
What this could lead to: If this bacterium is safe and well-tolerated, it could pave the way for larger studies exploring whether it helps improve metabolic health in people with obesity or type 2 diabetes.
What could go wrong: This is a very early, small Phase 1 trial with only 20 participants. It only tests safety and tolerability for 15 days, so it cannot show any health benefits. Mild digestive side effects like bloating or gas are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTH OBESITY & OVERWEIGHT OBESITY TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC)

Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.